Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | RORC | P51449 | 3/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27261553 | 0.76 | SMN1; SMN2 (0.47) | SMN1; SMN2ALDH1A1MAPK1POLBHTT | |
| SCHEMBL12806712 | 0.76 | ALDH1A1 (0.47) | SMN1; SMN2ALDH1A1MAPK1POLBHTT | |
| SCHEMBL22690074 | 0.75 | SMN1; SMN2 (0.50) | SMN1; SMN2ALDH1A1MAPK1POLBHTT | |
| SCHEMBL29374065 | 0.75 | SMN1; SMN2 (0.50) | SMN1; SMN2ALDH1A1MAPK1POLBHTT | |
| SCHEMBL22655924 | 0.71 | SMN1; SMN2 (0.46) | SMN1; SMN2ALDH1A1MAPK1POLBHTT | |
| SCHEMBL1484535 | 0.69 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL22251108 | 0.67 | SMN1; SMN2 (0.50) | SMN1; SMN2ALDH1A1MAPK1POLBHTT | |
| SCHEMBL31214371 | 0.67 | HSP90AA1 (0.35) | SMN1; SMN2ALDH1A1MAPK1POLBHTT | |
| SCHEMBL24070948 | 0.67 | KLKB1 (0.37) | — | |
| SCHEMBL10411734 | 0.66 | SMN1; SMN2 (0.54) | SMN1; SMN2ALDH1A1MAPK1POLBHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239788-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239788-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | KRAS, NRAS, HRAS | SMN1; SMN2 1713/4885ALDH1A1 2871/4885MAPK1 332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.